Aurobindo Pharma has received final USFDA to manufacture and market Rivastigmine Tartrate Capsules USP which is used for the treatment of dementia disease, in the American market. The approved product is bioequivalent and therapeutically equivalent to Novartis Pharmaceuticals Corporation’s Exelon Capsules. The drug Rivastigmine has an estimated market size of USD 26.7 million for the twelve months ending January 2016. The drug Exelon is used in the treatment of mild moderate dementia of the Alzheimer’s and Parkinson’s disease.
Company Profile : Aurobindo Pharma Ltd
Leave a Reply